These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38405079)

  • 61. ERRγ ligand HPB2 upregulates BDNF-TrkB and enhances dopaminergic neuronal phenotype.
    Kim HI; Lee S; Lim J; Chung S; Koo TS; Ji YG; Suh YG; Son WS; Kim SH; Choi HJ
    Pharmacol Res; 2021 Mar; 165():105423. PubMed ID: 33434621
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson's disease.
    Tassan Mazzocco M; Serra M; Maspero M; Coliva A; Presotto L; Casu MA; Morelli M; Moresco RM; Belloli S; Pinna A
    Exp Neurol; 2024 Apr; 374():114704. PubMed ID: 38281587
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
    Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
    Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of the micro-immunotherapy medicine 2LPARK
    Lilli NL; Révy D; Robelet S; Lejeune B
    Degener Neurol Neuromuscul Dis; 2019; 9():79-88. PubMed ID: 31372089
    [TBL] [Abstract][Full Text] [Related]  

  • 65. L-alpha-aminoadipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinson's disease in male rats.
    O'Neill E; Chiara Goisis R; Haverty R; Harkin A
    J Neurosci Res; 2019 Jul; 97(7):804-816. PubMed ID: 30924171
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson's disease: focus on endogenous neurorestoration.
    'Episcopo FL; Tirolo C; Testa N; Caniglia S; Morale MC; Marchetti B
    Curr Aging Sci; 2013 Feb; 6(1):45-55. PubMed ID: 23895521
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Rai SN; Yadav SK; Singh D; Singh SP
    J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Overview of tyrosine hydroxylase in Parkinson's disease.
    Zhu Y; Zhang J; Zeng Y
    CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):350-8. PubMed ID: 22483316
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Trichloroethylene and Parkinson's Disease: Risk Assessment.
    Liu M; Shin EJ; Dang DK; Jin CH; Lee PH; Jeong JH; Park SJ; Kim YS; Xing B; Xin T; Bing G; Kim HC
    Mol Neurobiol; 2018 Jul; 55(7):6201-6214. PubMed ID: 29270919
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.
    Nagatsu T; Nakashima A; Watanabe H; Ito S; Wakamatsu K; Zucca FA; Zecca L; Youdim M; Wulf M; Riederer P; Dijkstra JM
    J Neural Transm (Vienna); 2023 May; 130(5):611-625. PubMed ID: 36939908
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of type 1 diabetes mellitus as a risk factor of Parkinson's disease in a Drosophila model.
    Sanz FJ; Martínez-Carrión G; Solana-Manrique C; Paricio N
    J Exp Zool A Ecol Integr Physiol; 2023 Oct; 339(8):697-705. PubMed ID: 37381093
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Changes in Tyrosine Hydroxylase Activity and Dopamine Synthesis in the Nigrostriatal System of Mice in an Acute Model of Parkinson's Disease as a Manifestation of Neurodegeneration and Neuroplasticity.
    Kolacheva A; Alekperova L; Pavlova E; Bannikova A; Ugrumov MV
    Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741664
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selective loss of dopaminergic neurons in the substantia nigra pars compacta after systemic administration of MPTP facilitates extinction learning.
    Kinoshita K; Tada Y; Muroi Y; Unno T; Ishii T
    Life Sci; 2015 Sep; 137():28-36. PubMed ID: 26209139
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Protease-activated receptor 1 (PAR1) inhibits synaptic NMDARs in mouse nigral dopaminergic neurons.
    Price R; Ferrari E; Gardoni F; Mercuri NB; Ledonne A
    Pharmacol Res; 2020 Oct; 160():105185. PubMed ID: 32891865
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase.
    Zhang J; Graham DG; Montine TJ; Ho YS
    J Neuropathol Exp Neurol; 2000 Jan; 59(1):53-61. PubMed ID: 10744035
    [TBL] [Abstract][Full Text] [Related]  

  • 78. LUHMES Cells: Phenotype Refinement and Development of an MPP
    Beliakov SV; Blokhin V; Surkov SA; Ugrumov MV
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614176
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.
    Langley MR; Ghaisas S; Ay M; Luo J; Palanisamy BN; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2018 Jan; 64():240-255. PubMed ID: 28595911
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.